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Summary
Objective: To describe hepatitis C virus (HCV) and HIV prevalence and co-infection, and to
examine variables associated with infection in a community sample of men who have sex with
men (MSM).
Methods: Data were from an anonymous, cross-sectional study (N = 5080) in Canada. Men self-
completed a questionnaire and provided an optional saliva specimen for HCV and HIV testing.
Polytomous logistic regressions identified variables associated with HCV, HIV, and HCV—HIV co-
infection.
Results: The prevalences of HCV, HIV, and HCV—HIV co-infection were 1.9%, 9.0%, and 0.7%,
respectively. The greatest contribution to HCV (odds ratio (OR) 23.66, 95% confidence interval (CI)
9.69—57.73) and HCV—HIV co-infection (OR 26.76, 95% CI 7.97—89.80) was injection drug use.
Sexual behaviors and proxies were associated with HIV but not HCV infection.
Conclusions: Results suggest there are subgroups of MSM at risk for HCV. While sexual transmis-
sion of HCVwas not ruled out, the predominant risk was needle sharing. The greater prevalence of
HCVamong HIV-positivemen suggests the need for greater vigilance in the detection of HCV in this
group.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Worldwide, few studies have been undertaken to determine
the prevalence of hepatitis C virus (HCV) or to examine social
and other behavioral risk factors associated with this infec-
tion in a community sample. Most HCV prevalence estimates
have been derived from modeling of data from clinic and
laboratory populations and through cohort studies.1 Clinical
and population-based studies have predominantly captured
heterosexual populations and many have excluded known
homosexual populations. Methods have not been designed to
include marginalized and difficult to sample groups such as
gay and bisexual men.
HCV prevalence varies greatly from country to country
and from region to region.1 It is estimated that one third of
HIV-positive persons worldwide are co-infected with HCV.2
While estimates of co-infection rates vary among ‘at-risk’
populations, co-infections occur most frequently among
injection drug users (IDUs).3—5 Concern about co-infection
among HIV-infected populations exists for a number of rea-
sons. HIV-infected people are more likely to be susceptible
to HCV morbidity,3 and co-infection is thought to accelerate
HIV disease progression. Further, persons co-infected with
HCVand HIV exhibit more rapid progression to liver cirrhosis
and liver failure.6—10 Available treatments for co-infection
are challenging and complex.2
Given what is known about transmission, research identi-
fying HCV and HCV—HIV co-infection has mainly focused on
IDUs. A large number of studies have shown that HCV pre-
valence among HIV-infected IDUs is higher than HIV-negative
IDUs. Several studies have found increased prevalence of HCV
among men who have sex with men (MSM) compared with the
general population.11—17 The contribution of sexual activities
between gay and bisexual men to HCV transmission has been
somewhat equivocal.11—13,18 There are a number of reasons
why gay and bisexual male populations may be at risk for HCV.
First, considerable drug use and potential mixing with injec-
tion drug using populations may place those in the gay
community at risk for HCV. For example, in a study of gay
and bisexual men who use drugs other than alcohol or
marijuana, 52% reported needle use at least once in their
lifetime.19 Millson et al. (1995) reported that rates of HIV
infection among male IDUs who have sex with men (29%) are
higher than other male IDUs in a community sample (4.9%).20
Second, with the repertoire of sexual activities practiced by
gay and bisexual men, rectal trauma may result in an
increased potential for direct exposure to blood.21,22 While
Craib (2004) found the predominant factor associated with
HCV infection among MSM to be injection drug use, he also
identified the sexual practice of insertive fisting to be mar-
ginally associated with HCV seropositivity.23 Rauch and col-
leagues have found unprotected anal intercourse to be
associated with increased incidence of HCV infection among
MSM.26
The purpose of this study was to assess the prevalence of
HCV and HCV—HIV co-infection in a community sample of
gay and bisexual men. The specific objectives were to
ascertain HCV prevalence, to examine the extent of co-
infection with HIV, and to undertake investigations of
variables and factors associated with HCV infection and
HCV—HIV co-infection.Methods
Study population
The data used for this analysis were from an anonymous,
cross-sectional study of socio-behavioral issues and sexual
health in a community sample of gay and bisexual men in
Ontario, Canada. The survey was based in venues, including
bars and bathhouses, and community groups in 13 cities/
regions. A purposive sampling strategy was utilized to recruit
a diverse sample of gay and bisexual men.
Only men over the age of 15 years were included.
Informed consent was obtained verbally from all participants
prior to data collection. The study received approval from
the University of Toronto Research Ethics Board.
Data collection
Data collection was conducted by trained coordinators and
volunteer recruiters. A self-report questionnaire was avail-
able in seven languages (English, French, Chinese, Portu-
guese, Spanish, Tamil, and Vietnamese). The sampling
strategy was developed prior to entry in the field through
an assessment of the patterns of socialization (i.e., number
of venues, groups, days of week for special events, etc.).
Over 418 recruitment sessions, varied by day-of-week and
time-of-day were conducted. The number of respondents
recruited in each venue was determined by the venue size.
A systematic sampling approach was utilized to ensure that
individuals frequenting venues at different points in time
were selected.
The questionnaire sought information on sociodemo-
graphic and personal characteristics, socialization, sexual
health, patterns of partner seeking, sexual relationships,
condom use, sexual behavior (lifetime, past 12 months,
and past 3 months), substance use, and HIV testing. Upon
completion of the questionnaire, respondents were given the
option to provide a saliva specimen. The saliva specimen was
collected with an Omni-SalTM device. Completed anonymous
questionnaires and saliva specimens were coded with unique
identifiers prior to analysis.
Laboratory methods
HIV and HCV antibody testing were conducted at the Central
Public Health Laboratory, Ontario Ministry of Health and
Long-Term Care. The hepatitis C screen test was performed
using the Ortho Diagnostic HCV 3.0 SAVe ELISA test kit and the
confirmatory testing was performed using the Bio-Rad Mono-
lisa anti-HCV Plus version 2. The sensitivity of the assay
ranged from 72% to 88% and the specificity ranged from
89% to 100%.25 Fluid specimens were tested for the HIV
antibody using the Biochem Detect HIV v1 test kit, an enzyme
linked immunoassay (ELISA). Reactive specimens were con-
firmed with the Vironostika HIV-1 Micro-ELISA system (bio-
Merieux, Organon Teknika). The Vironostika assay was
sensitive (98.7%) and highly specific (100%). If the second
test was not reactive (indeterminate or negative), the dis-
crepancy was resolved using a Genetic Systems HIV-1Western
Blot (Bio-Rad).
Table 1 The characteristics of participants providing sufficient saliva for HCV and HIV testing and those not providing saliva
Variables No saliva provided
(N = 1445)
Sufficient saliva provided
(N = 3304)
n (%) Mean (SD) n (%) Mean (SD)
Sociodemographic
Age 34.9 (11.1) 35.5 (11.8)
First languagea
English 1101 (76.7) 2624 (80.0)
Other 334 (23.3) 656 (20.0)
Educationa
High school or less 364 (25.3) 743 (22.6)
College or university 907 (63.2) 2084 (63.4)
Graduate education 165 (11.5) 458 (13.9)
Employment statusa
In labor force 1128 (78.8) 2431 (74.4)
Not in labor force 304 (21.2) 836 (25.6)
Student status (yes) 284 (20.3) 658 (20.4)
Personal income
Less than $29 999 565 (40.9) 1384 (43.1)
$30 000—$59 999 557 (40.4) 1195 (37.2)
$60 000 or more 258 (18.7) 635 (19.8)
Ethnicitya
Caucasian 1117 (77.3) 2703 (81.8)
Other 328 (22.7) 601 (18.2)
Aboriginal (yes) 50 (3.7) 89 (2.8)
Country of birtha
Canada 993 (76.7) 2436 (80.0)
Other 302 (23.3) 610 (20.0)
Years lived in Canadaa 30.1 (14.0) 31.5 (14.3)
Social life
Gay bar attendance
Never or <2/year 643 (45.9) 1480 (45.7)
1—3/month 577 (41.2) 1376 (42.5)
>3/month 182 (13.0) 384 (11.9)
Straight bar attendancea
Never or <2/year 244 (17.6) 482 (14.9)
1—3/month 554 (39.9) 1282 (39.6)
>3/month 591 (42.5) 1474 (45.5)
Bathhouse attendance
Never or <2/year 82 (5.9) 151 (4.7)
1—3/month 286 (20.7) 682 (21.1)
>3/month 1016 (73.4) 2401 (74.2)
Gay dance, events or parties attendancea
Never or <2/year 159 (11.4) 360 (11.1)
1—3/month 541 (38.9) 1461 (45.2)
>3/month 691 (49.7) 1412 (43.7)
Members of an organized gay or
bisexual group or organization
not AIDS-related (yes) a
294 (21.0) 866 (27.7)
Sexual identity
Gay 1136 (81.4) 2716 (84.0)
Bisexual 190 (13.6) 386 (11.9)
Other 70 (5.0) 133 (4.1)
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Table 1 (Continued )
Variables No saliva provided
(N = 1445)
Sufficient saliva provided
(N = 3304)
n (%) Mean (SD) n (%) Mean (SD)
Sexual health
Oral gonorrhea (ever) 48 (3.3) 130 (3.9)
Rectal gonorrhea (ever) 40 (2.8) 84 (2.5)
Urethral gonorrhea (ever) a 105 (7.3) 319 (9.7)
Chlamydia (ever) a 59 (4.1) 184 (5.6)
Genital or anal warts (ever) a 102 (7.1) 300 (9.1)
Syphilis (ever) a 27 (1.9) 114 (3.5)
Genital herpes (ever) 30 (2.1) 100 (3.0)
Hepatitis A (ever) a 46 (3.2) 149 (4.5)
Hepatitis B (ever) 65 (4.5) 170 (5.1)
Sex life
Total number of male sex partners in the past 12 monthsa
1 324 (25.3) 705 (23.7)
2—4 418 (32.7) 899 (30.2)
5 538 (42.0) 1376 (46.2)
Paid money to a male for sex in the
past 12 months (yes)
86 (6.6) 186 (6.2)
Received money for sex from a male
in the past 12 months (yes)
96 (7.4) 207 (6.9)
Gave drugs, goods, clothing, protection,
or shelter to a male for sex
in the past 12 months (yes)
46 (3.6) 123 (4.1)
Received drugs, goods, clothing, protection,
or shelter from a male for sex
in the past 12 months (yes)
63 (4.9) 149 (4.9)
UIAI (ever) a 706 (55.0) 1915 (64.1)
URAI (ever) a 660 (51.5) 1722 (57.7)
Genital modification
Circumcised (cut) (yes) 900 (63.8) 2118 (64.7)
Genital piercing (yes) 29 (2.1) 90 (2.8)
SD, standard deviation; UIAI, unprotected insertive anal intercourse with a man; URAI, unprotected receptive anal intercourse with a man.
a p < 0.05.
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We carried out descriptive analyses of the sample including
the distribution of key sociodemographic and personal
characteristics, socialization, sexual health, sex life, and
recreational drug use variables. Only participants providing
sufficient saliva for testing were included in the univariate
and multivariate analyses. Categorical variables were
dummy coded. Univariate and multivariate polytomous
logistic regressions were used to identify the variables
associated with the presence of HCV infection only, HIV
infection only, and HCV—HIV co-infection relative to indi-
viduals who had no infection. Crude odds ratios (COR),
adjusted odds ratios (AOR), and 95% confidence intervals
(CI) were calculated. A backward selection process was
used to identify factors associated with the outcome. If the
p-value of the variable was less than or equal to 0.20 in
the univariate polytomous analysis, it was entered into the
multivariate polytomous analysis. The significance levelrequired for inclusion was set at 0.05. All analyses were
performed using SAS, version 9.1 (SAS Institute Inc., Cary,
NC, USA).
Results
Study sample characteristics
In total, 5080 men participated in the survey. Of these, 3635
(71.6%) participants provided saliva and 3304 (65.0%) of speci-
menscollectedcontainedsufficientfluid toconduct laboratory
tests to detect the presence of both HCV and HIV antibodies.
Table 1 compares the characteristics of the participants
who provided sufficient saliva for HIV and HCV biological
testing with the characteristics of those who did not provide
saliva. The 331 (6.5%) men who provided saliva but whose
saliva was not sufficient for HCVand HIV biological testing and
who were excluded from univariate and multivariate analysis
did not differ from men who had sufficient saliva.
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For those who provided sufficient saliva, more than half
(60.2%) reported the use of recreational drugs in the previous
12 months. The most commonly used drugs were marijuana/
hash (46.9%), poppers (21.3%), ecstasy (19.7%), cocaine
(17.5%), and special K (12.9%). Further, 185 (5.7%) reported
using a needle to inject a recreational drug in their lifetime.
HCV, HIV, and HCV—HIV prevalence
In this sample, the overall HCV prevalence was 1.9% and the
overall HIV prevalence was 9.0%. The prevalence rates of HCV
infection only, HIV infection only, and HCV—HIV co-infection
among men providing sufficient saliva (i.e., the sample
examined in the regression analysis), were 1.2% (0.86—
1.6%), 8.3% (7.4—9.3%), and 0.7% (0.41—0.98%), respectively.Table 2 HCV, HIV, and HCV—HIV prevalence and prevalence rati
Categories HCV prevalence (n) a PR HIV prevale
Overall 1.9% (64) 9.0% (298)
HCV status
Positive 35.9% (23)b
Negative 8.5% (275)
HIV status
Positive 7.7% (23)b 5.5
Negative 1.4% (41) 1.0
Recreational drug user (past 12 months)
Yes 2.7% (54)b 3.6 11.2% (222)
No 0.76% (10) 1.0 5.8% (76)
Injection drug use
Ever 19.5% (36)b 25.7 28.1% (52)b
Never 0.76% (23) 1.0 7.8% (236)
Sexual identity
GBI 1.6% (10)b 0.21 9.3% (6)
Other 7.5% (50) 1.0 4.5% (288)
HIV-positive
GBI
Other
Recreational drug users
GBI 2.4% (44) 1.0 11.6% (216)
Other 2.3% (1) 1.0 4.7% (2)
Injection drug users
GBI 17.8% (29)b 6.8 30.1% (49)b
Other 2.6% (3) 1.0 1.8% (2)
PR, prevalence ratio; GBI, gay or bisexual identified.
a Number may vary based on questionnaire item response.
b p-Value of Chi-square test is less than 0.05.Table 2 presents the HCV, HIV, and HCV—HIV prevalence and
prevalence ratios for various subgroups of individuals.
Univariate analyses
Univariate polytomous logistic regressions were undertaken
to examine the relationship of sociodemographic and perso-
nal characteristics, socialization, sexual health, sex life, and
drug use variables with HCV infection, HIV infection, and
HCV—HIV co-infection (see Table 3).
Multivariate analyses
Multivariate polytomous logistic regressions were used to
examine the associations among selected variables and
HCV infection, HCV—HIV co-infection, and HIV infection indi-
vidually in relation to no infection (see Table 4).os (N = 3304)
nce (n) a PR HCV—HIV prevalence (n) a PR
0.7% (23)
4.2
1.0
b 1.9 1.0% (20)b 4.3
1.0 0.23% (3) 1.0
3.6 7.6% (14)b 33
1.0 0.23% (7) 1.0
2.1 0.64% (20)b 0.28
1.0 2.3% (3) 1.0
6.9% (3)b 0.14
50.0% (20) 1.0
2.5 0.97% (18) 0.42
1.0 2.3% (1) 1.0
16.7 7.4% (12)b
0.0% (0)
Table 3 Univariate polytomous logistic regression (N = 3304)
Variables HCV infection only HCV—HIV co-infection HIV infection only
COR (95% CI) p-Value COR (95% CI) p-Value COR (95% CI) p-Value
Sociodemographic
Age 1.04 (1.02, 1.07) 0.0006 1.05 (1.02, 1.09) 0.0007 1.04 (1.03, 1.05) <0.0001
First language (other) a 0.94 (0.43, 2.05) NS 0.58 (0.17, 1.97) NS 0.74 (0.53, 1.04) 0.0800
Educationb
College or university 0.31 (0.16, 0.60) 0.0005 0.34 (0.14, 0.83) 0.0175 0.90 (0.67, 1.20) 0.4624
Graduate 0.40 (0.15, 1.08) 0.0707 0.46 (0.13, 1.67) NS 0.57 (0.36, 0.92) 0.0196
Employment status c
Not in labor force 1.72 (0.88, 3.39) 0.1146 11.94 (4.42, 32.26) <0.00012.80 (2.17, 3.60) <0.0001
Student status (yes) d 10.71 (1.47,78.12) 0.0194 6.20 (0.83, 46.07) 0.0747 3.72 (2.32, 5.98) <0.0001
Personal incomee
Less than $29 999 1.24 (0.54, 2.81) NS 2.82 (0.83, 9.64) 0.0965 1.22 (0.86, 1.74) NS
$30 000—$59 999 0.60 (0.23, 1.57) NS 0.18 (0.019, 1.72) 0.1363 1.24 (0.87, 1.79) NS
Ethnicity (other) f 0.49 (0.17, 1.37) 0.1716 1.25 (0.46, 3.38) NS 1.05 (0.76, 1.44) NS
Country of birth (other) g 0.75 (0.31, 1.80) NS 0.71 (0.21, 2.42) NS 1.08 (0.78, 1.48) NS
Social life
Gay bar attendanceh
1—3 times a month 1.05 (0.39, 2.84) NS 0.55 (0.19, 1.63) NS 0.99 (0.66, 1.49) NS
>3 times a month 0.77 (0.28, 2.13) NS 0.36 (0.11, 1.14) 0.0820 1.01 (0.67, 1.52) NS
Straight bar attendanceh
1—3 times a month 1.12 (0.54, 2.30) NS 0.92 (0.38, 2.22) NS 0.73 (0.56, 0.95) 0.0183
>3 times a month 1.73 (0.75, 3.98) 0.1976 0.52 (0.12, 2.37) NS 0.40 (0.25, 0.64) 0.0001
Bathhouse attendanceh
1—3 times a month 1.35 (0.63, 2.89) NS 2.10 (0.83, 5.28) 0.1160 2.54 (1.94, 3.33) <0.0001
>3 times a month 2.09 (0.63, 7.01) NS 4.19 (1.18, 14.88) 0.0270 2.78 (1.73, 4.47) <0.0001
Member of an organized gay or
bisexual group or organization
that is not AIDS-related (no) i
1.42 (0.65, 3.11) NS 1.80 (0.61, 5.30) NS 1.43 (1.06, 1.94) 0.0195
Identityj
Gay 0.16 (0.068, 0.39) <0.0001 0.23 (0.065, 0.81) 0.0225 4.10 (1.29, 12.98)0.0165
Bisexual 0.34 (0.12, 0.99) 0.0471 0.68 (0.17, 2.75) NS 2.15 (0.62, 7.38) NS
Sexual health
Oral gonorrhea (ever) k 0.74 (0.10, 5.43) NS 2.82 (0.65, 12.18) 0.1659 3.62 (2.36, 5.56) <0.0001
Rectal gonorrhea (ever) k 2.82 (0.66, 11.97) 0.1605 5.24 (1.20, 22.89) 0.0279 5.98 (3.70, 9.68) <0.0001
Urethral gonorrhea (ever) k 0.88 (0.27, 2.87) NS 1.67 (0.49, 5.67) NS 3.74 (2.76, 5.05) <0.0001
Chlamydia (ever) k 0.46 (0.063, 3.37) NS 0.84 (0.11, 6.24) NS 2.17 (1.43, 3.29) 0.0003
Genital or anal warts (ever) k 1.71 (0.66, 4.40) NS 2.59 (0.87, 7.68) 0.0863 4.04 (2.97, 5.49) <0.0001
Genital herpes (ever) k 1.05 (0.14, 7.74) NS 6.30 (1.83, 21.69) 0.0035 4.57 (2.88, 7.26) <0.0001
Hepatitis A (ever) k 1.43 (0.34, 5.98) NS 12.16 (4.90, 30.20) <0.00014.32 (2.90, 6.43) <0.0001
Hepatitis B (ever) k 1.92 (0.59, 6.32) NS 3.65 (1.07, 12.46) 0.0386 5.02 (3.49, 7.22) <0.0001
Sex life
Total number of male sex partners
in the past 12 months l
2—4 0.96 (0.41, 2.23) NS 5.59 (0.69, 45.55) 0.1078 1.21 (0.81, 1.80) NS
5 0.59 (0.25, 1.41) NS 5.40 (0.69, 42.25) 0.1083 1.87 (1.32, 2.66) 0.0005
Paid money to a male for sex in
the past 12 months (yes) d
0.96 (0.23, 4.03) NS 0.85 (0.11, 6.40) NS 1.07 (0.64, 1.79) NS
Received money for sex from a
male in the past
12 months (yes)d
2.63 (1.01, 6.90) 0.0491 2.76 (0.80, 9.58) 0.1089 1.70 (1.11, 2.61) 0.0149
Gave drugs, goods, clothing,
protection, or shelter to a
male for sex in the past
12 months (yes)d
2.78 (0.84, 9.27) 0.0955 11.06 (3.86, 31.68) <0.00012.91 (1.82, 4.66) <0.0001
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Variables HCV infection only HCV—HIV co-infection HIV infection only
COR (95% CI) p-Value COR (95% CI) p-Value COR (95% CI) p-Value
Received drugs, goods, clothing,
protection, or shelter from a
male for sex in the past
12 months (yes) d
1.49 (0.35, 6.30) NS 11.93 (4.39, 32.37) <0.00013.33 (2.20, 5.06) <0.0001
UIAI (ever) k 0.53 (0.27, 1.04) 0.0641 2.22 (0.74, 6.72) 0.1567 2.21 (1.62, 3.01) <0.0001
URAI (ever) k 0.58 (0.29, 1.17) 0.1296 2.22 (0.80, 6.18) 0.1267 2.88 (2.12, 3.92) <0.0001
Genital modification
Circumcised (yes) d 0.76 (0.38, 1.54) NS 0.87 (0.35, 2.14) NS 1.04 (0.80, 1.34) NS
Genital piercing (yes)d 1.03 (0.14, 7.61) NS 1.86 (0.25, 14.05) NS 2.28 (1.29, 4.03) 0.0047
Drug use
Recreational drug use in
the past 12 months (yes) d
3.46 (1.53, 7.83) 0.0029 4.75 (1.41, 16.01) 0.0120 1.97 (1.49, 2.60) <0.0001
Used a needle to inject a
recreational drug (ever) k
34.61 (17.69,67.73)<0.000150.34 (19.92,127.20)<0.00014.18 (2.82, 6.18) <0.0001
COR, crude odds ratio; CI, confidence interval; NS, not significant at 0.20 level; UIAI, unprotected insertive anal intercourse with a man;
URAI, unprotected receptive anal intercourse with a man.
Reference level: aEnglish; belementary/high school; cin labor force; dno; e$ 60 000 or more; fCaucasian; gCanada; hnever/less than twice a
year; iyes; jother; knever; lone.
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was associated with increasing age in all three groupings
(HCV infection, HCV—HIV co-infection, and HIV infection).
HCV and HCV—HIV co-infection were not associated with
education. However, HIV infection was less likely to be
associated with those with graduate education compared
to those with high school education or less. HCV—HIV co-
infection as well as HIV infection weremore likely to be found
among those who were not in the labor force compared to
those who were.
HCV, HIV, and HCV—HIV co-infection were not associated
with gay bar or straight bar attendance. Men who attended
bathhouses one to three times amonth weremore likely to be
HIV-infected compared to those who never attended or
attended bathhouses less than twice a year (AOR 2.03, 95%
CI 1.49—2.76).
Similar to socializing variables, a number of sexually trans-
mitted diseases (STDs) dropped out in the multivariate ana-
lysis. Nevertheless, urethral gonorrhea and genital or anal
warts were associated with HIV infection. Men who had ever
had hepatitis Avirus (HAV)weremore likely to beHCV—HIV co-
infected compared to those who never had (AOR 16.64, 95% CI
4.17—66.36; p < 0.0001). This association is somewhat diffi-
cult to explain based simply on route of transmission. Themain
source of HAV transmission is fecal and the main source of
transmission for HCV and HIV is through blood or semen,
respectively. It is possible that individuals who are HCV—HIV
co-infected may engage in a wider range of sexual activities,
which may include oral—anal contact and oral sex, where HAV
transmission is more likely to occur. Our data on unprotected
oral, and oral—anal sex did not adequately permit us to
examine this. Also, it is possible that HCV—HIV co-infection
may accelerate the likelihood of becoming HAV-infected.
Further, men who were ever infected with hepatitis B were
more likely to be HIV-infected compared to others (AOR 1.98,
95% CI 1.24—3.14; p = 0.0040).Unprotected receptive anal intercourse was associated
with HIV infection (AOR 2.14, 95% CI 1.52—2.99; p < 0.0001)
but not with HCV or HCV—HIV co-infection. Receipt of drugs,
goods, clothing, protection, or shelter from a male in
exchange for sex was not associated with HCV infection
but was associated with HCV—HIV co-infection and HIV infec-
tion; and there was a stronger association with HCV—HIV co-
infection (AOR 7.18, 95% CI 1.81—28.45; p = 0.0050) than HIV
infection (AOR 2.38, 95% CI 1.41—4.00; p = 0.0011). Further,
no associations were found for the receipt of money in
exchange for sex.
Variables most strongly associated with HCVand HCV—HIV
co-infection were recreational drug use and injection drug
use. For injecting drugs, the respective AORs were 23.66 (95%
CI 9.69—57.73; p < 0.0001) and 26.76 (95% CI 7.97—89.80;
p < 0.0001). For recreational drug use, the respective AORs
were 18.81 (95% CI 2.44—144.89; p = 0.0048) and 11.76 (95%
CI 1.21—114.57; p = 0.0340).
Discussion
While HCV prevalence is thought to be higher in the general
population than HIV prevalence, in this gay and bisexual
community sample HCV prevalence was found to be lower
than HIV prevalence. Although, in some regards, HCV infec-
tion may not be a major concern in the gay and bisexual
community at large, the finding that HCV prevalence in the
gay and bisexual community is slightly higher than in the
general population in Canada suggests there may be concern
for some subgroups of men, specifically MSM who are also
recreational drug users and/or IDUs. In this analysis, the
greatest contribution to HCV infection and HCV—HIV co-
infection were injection and recreational drug use. Personal
income, ethnicity, sexual identity, gay bar attendance, and
professional sex work (i.e., sex for money) were not asso-
ciated with HCV infection in this analysis. Sex for drugs or
Table 4 Multivariate polytomous logistic regression (N = 3304)
Variables HCV infection only HCV—HIV co-infection HIV infection only
AOR (95% CI) p-Value AOR (95% CI) p-Value AOR (95% CI) p-Value
Sociodemographic
Agea 1.07 (1.03, 1.11) 0.0001 1.10 (1.04, 1.15) 0.0005 1.03 (1.01, 1.04) <0.0001
Educationb
College/university 0.42 (0.17, 1.04) 0.0612 0.48 (0.15, 1.55) 0.2196 0.95 (0.67, 1.35) 0.7668
Graduate 0.65 (0.18, 2.35) 0.5118 0.39 (0.062, 2.42) 0.3102 0.42 (0.24, 0.73) 0.0020
Employment status c
Not in labor force 0.98 (0.40, 2.41) 0.9644 7.21 (1.96, 26.69) 0.0031 2.51 (1.86, 3.40) <0.0001
Social life
Bathhouse attendanced
1—3 times a month 1.05 (0.42, 2.59) 0.9248 1.48 (0.44, 4.99) 0.5288 2.03 (1.49, 2.76) <0.0001
>3 times a month 0.86 (0.17, 4.36) 0.8531 2.76 (0.57, 13.44) 0.2076 1.59 (0.89, 2.84) 0.1193
Sexual health
Urethral gonorrhea (ever)e 0.37 (0.079, 1.77) 0.2143 0.13 (0.020, 0.83) 0.0312 1.74 (1.20, 2.53) 0.0038
Genital or anal warts (ever)e 2.12 (0.69, 6.54) 0.1904 2.40 (0.58, 9.90) 0.2244 2.60 (1.80, 3.77) <0.0001
Hepatitis A (ever)e 1.10 (0.19, 6.24) 0.9154 16.64 (4.17, 66.36) <0.0001 1.51 (0.89, 2.54) 0.1264
Hepatitis B (ever)e 1.69 (0.40, 7.12) 0.4766 0.33 (0.05, 1.96) 0.2212 1.98 (1.24, 3.14) 0.0040
Sex life
Received drugs, goods, clothing,
protection, or shelter from a
male for sex in the past
12 months (yes) f
0.54 (0.07, 4.42) 0.5650 7.18 (1.81, 28.45) 0.0050 2.38 (1.41, 4.00) 0.0011
URAI (ever)e 0.28 (0.12, 0.68) 0.0046 1.13 (0.31, 4.10) 0.8564 2.14 (1.52, 2.99) <0.0001
Drug use
Recreational drug use in
the past 12 months (yes)a,f
18.81 (2.44,144.89) 0.0048 11.76 (1.21,114.57) 0.03399 1.46 (1.05,2.10) 0.0267
Used a needle to inject a
recreational drug (ever)a,e
23.66 (9.69, 57.73) <0.0001 26.76 (7.97, 89.80) <0.0001 1.18 (1.10, 2.99) <0.0202
AOR, adjusted odds ratio; CI, confidence interval; URAI, unprotected receptive anal intercourse with a man.
ap <0.05 for HCV infection, HIV infection and HCV—HIV co-infection.
Reference level: belementary/high school; cin labor force; dnever/less than twice a year; enever; fno.
R-square = 0.20, max-rescaled R-square = 0.29.
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and proxies for sexual risk behavior, such as STDs, were
associated with HIV infection but not HCV infection.
In Canada, the HCV prevalence in the population at large
was estimated to be 0.8% in 2002.27 The HCV prevalence for
the USA population at large has been estimated to be 1.8%.28
The overall HCV prevalence for men in this sample was 1.9%.
Based on the male population in Ontario, we calculated the
age standardized prevalence rate for our sample to be 1.7%,
which is higher than the estimated rate of 1.14% for the total
male population of the province.29 No estimates of the HCV
prevalence in a community sample of gay and bisexual men in
Canada have been previously available. Internationally,
information on the prevalence of HCVamong gay and bisexual
men suggests it may range from 3% to 14%, which demon-
strates considerable variation in HCV infection by country
and sampling frame.1,11,18,30,31 In this community sample, we
found that HCV prevalence was higher among HIV-positive
men compared to HIV-negative men, but was lower amongself-identified gay and bisexual men compared with those
with other identities. Univariate analysis suggests associa-
tions between sexual identity (gay/bisexual versus other)
and HCV infection; however, these associations disappeared
in the multivariate analysis. Despite the lifetime prevalence,
this suggests self-identified gay and bisexual men may not be
at increased risk for HCV infection.
The overall HCV—HIV co-infection prevalence among men
in our analysis was 0.7%. In our sample among HIV-positive
individuals, 7.7% were HCV-positive, and among HCV-positive
individuals 35.9% were HIV-positive. In Canada, a study con-
ducted in an HIV laboratory in Alberta found a prevalence of
9.3% among 54 HIV-positive men;32 another study in general
practice clinics in Vancouver reported an HCV rate of infec-
tion of 8.8% among 352 HIV-infected men;33 and a cohort
study of HIV-negative MSM conducted in Montreal reported an
HCV prevalence of 2.9%.34 In a review of 15 international
studies of HCV—HIV co-infection among MSM, the rates of co-
infection ranged from 0% to 14%.1
738 T. Myers et al.In the current study, 5.7% reported ever using needles to
inject recreational drugs. This study confirms that injection
drug use is the predominant mode of HCV infection and HCV—
HIV co-infection among the men in the sample, which agrees
withtheresults foundinEurope,Australia,andtheUSA.14,35—39
Our data on related risk factors show an association
between STDs, a proxy for lifetime sexual behavior, specifi-
cally urethral gonorrhea and genital or anal warts, and HIV
infection but not HCV infection. There are equivocal data
regarding the association between the number of sex part-
ners and HCV infection.32,40,41 In this analysis, an association
was found with the number of sexual partners in the uni-
variate analysis but not in the multivariate analysis. Further,
HCV—HIV co-infection differed between some subpopula-
tions. Additional study of the differences between subpopu-
lations is important.25,26
In our analysis, HIV-positive men were 5.5 times more
likely to be HCV-infected compared to those who were HIV-
negative. This may suggest that HCV is associated with
specific sexual behaviors among people who are HIV-infected
and perhaps the increased vulnerability to HCV infection
among those who are HIV-positive. The finding of this analysis
is consistent with the results that have been found in Eur-
opean studies, which have shown outbreaks of HCV among
MSM who have high-risk sexual behaviors.42—45
In this sample of gay and bisexual men, more than half
took recreational drugs. Longitudinal studies are needed to
investigate and confirm the sexual risk of HCV transmission
among HIV-infected people, especially those who are not
IDUs.
There are limitations to our findings. Because the study
was cross-sectional, we could not determine when the men
acquired HIV and HCV, which presents challenges to the
understanding of causal relationships. Additional studies
using a prospective design are necessary to clarify the pre-
dictors of infection. The survey results relied on self-report
data. Therefore, as participants retrospectively report their
behavior, there may be inaccuracies in reporting lifetime
behavior. The study recruitment was primarily venue-based.
Methods were varied to ensure a broad and diverse sample,
but there may have been some community sectors who were
not represented or who were underrepresented. Also, our
study did not examine several identified sexual risk behaviors
for HCV infection among MSM, such as fisting.46
Our study provides important initial insights to be con-
sidered for targeting and enhancing existing prevention,
surveillance, and care initiatives. Due to the lack of an
effective vaccine for either HCV or HIV infection, increased
awareness, education, screening, and health services are
needed to help reduce disease transmission and infection.47
Identifying individuals who could benefit from behavioral and
medical intervention is vital in the effort to reduce HCV, HIV,
and HCV—HIV co-infection.
Our results suggest that within the gay and bisexual
community there are subgroups of men for whom HCV infec-
tion is a concern. This study confirms findings of other
studies, which indicate needle sharing to be the major mode
of transmission of HCV. The sexual transmission of HCV, if any,
would seem to account for a very small proportion of HCV
infections. Testing and counseling programs should clearly
distinguish between the risks for transmission of HCV and HIV
infection. Care for HIV-infected people needs to emphasizethe prevention of HCV infection and motivate MSM who are
HIV-positive to practice safer sex because of the additional
risk that may exist in transmitting and acquiring HCV infec-
tion. Clearly, for some men, such as men who may have few
options but to exchange sex for their survival, more struc-
tural and program supports are needed. Programs for MSM
need to consider some of the essential components of harm
reduction and provide options for addiction treatment for
those who require it.
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